Open AccessPanel testing reveals nonsense and missense CDH 1 mutations in families without hereditary diffuse gastric cancer
Author(s) -
Huynh Julie M.,
Laukaitis Christina M.
Publication year - 2016
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.197
Subject(s) - missense mutation , nonsense , nonsense mutation , medicine , cancer , genetics , mutation , cancer research , gene , biology
Background The reported penetrance of germline CDH 1 mutations is high in families with hereditary diffuse gastric cancer ( HDGC ). Men and women have a 70% and 56%, respectively, cumulative risk of developing diffuse gastric cancer by age 80. Women additionally have a 42% cumulative risk of developing breast cancer. Due to the high penetrance of these mutations, prophylactic total gastrectomy is currently recommended for CDH 1 mutation carriers. However, whether everyone with a CDH 1 gene mutation is at risk for HDGC is not clear. Methods Mutation identification was performed by next‐generation sequencing. Mutations and variant status was confirmed by Sanger sequencing in 11 family members. Results We present two families with pathogenic CDH 1 mutations. The first family carries a novel truncating, nonsense CDH 1 mutation that we were able to trace for three generations, but reports no family history of diffuse gastric cancer. The occurrence of cancer in this family deviates significantly from the expectation for HDGC . The proband from the second family presents with breast cancer and carries a previously reported pathogenic CDH 1 mutation, but also reports no family history of diffuse gastric cancer. Conclusions Our study demonstrates the need for further analysis of CDH 1 mutation penetrance in order to better counsel asymptomatic CDH 1 mutation carriers on preventative measures and general care.